Ultrasound-guided percutaneous portal transplantation of peripheral blood monocytes in patients with liver cirrhosis

Liver transplantation offers the only definite cure for cirrhosis but lacking donors is problem. Stem cell therapy is attractive in this setting. In this study, we aimed to explore the safety and efficacy of ultrasound-guided percutaneous portal transplantation of peripheral blood monocyte cell (PBM...

Full description

Saved in:
Bibliographic Details
Published inThe Korean journal of internal medicine Vol. 32; no. 2; pp. 261 - 268
Main Authors Yu, Su Jong, Yoon, Jung-Hwan, Kim, Won, Lee, Jeong Min, Lee, Yun Bin, Cho, Yuri, Lee, Dong Hyeon, Lee, Minjong, Yoo, Jeong-Ju, Cho, Eun Ju, Lee, Jeong-Hoon, Kim, Yoon Jun, Kim, Chung Yong
Format Journal Article
LanguageEnglish
Published Korea (South) The Korean Association of Internal Medicine 01.03.2017
대한내과학회
Subjects
Online AccessGet full text
ISSN1226-3303
2005-6648
2005-6648
DOI10.3904/kjim.2015.267

Cover

More Information
Summary:Liver transplantation offers the only definite cure for cirrhosis but lacking donors is problem. Stem cell therapy is attractive in this setting. In this study, we aimed to explore the safety and efficacy of ultrasound-guided percutaneous portal transplantation of peripheral blood monocyte cell (PBMC) in cirrhotic patients. A total of nine decompensated cirrhotic patients were randomized into three groups: group 1 (n = 3) was control group, group 2 (n = 3) received granulocyte-colony stimulating factor (G-CSF) mobilization for 3 days, and group 3 (n = 3) received G-CSF mobilized PBMCs by leukapheresis and PBMC transplantation through ultrasound-guided percutaneous portal vein puncture. Liver function and clinical features were evaluated. At baseline, the Child-Turcotte-Pugh and the model for end-stage liver disease scores were comparable in study groups. Compared with group 1, there was a tendency to improve liver function in group 3 at 6 months after treatment. Treatment was tolerable and no complications were encountered related to the G-CSF mobilization or percutaneous portal administration of PBMCs. Imaging studies showed patent portal veins at the end of the study period. Autologous PBMC transplantation through ultrasound-guided percutaneous portal vein puncture could be considered as a safe alternative treatment for decompensated cirrhotic patients.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ObjectType-Undefined-3
G704-001640.2017.32.2.024
ISSN:1226-3303
2005-6648
2005-6648
DOI:10.3904/kjim.2015.267